残余胃癌（RGC）的临床发现和术后随访数据由于其罕见而有限。此外，RGC 的术前分期、根治性手术和复发管理也提出了重大的临床挑战。我们分析了 17 个日本机构连续 313 名接受 RGC 根治性手术的患者的临床病理学结果、辅助化疗和术后复发模式。本研究探讨了 RGC 的最佳管理以及辅助化疗 (AC) 对无复发生存期 (RFS) 的影响。病理分期 I、II 和 III 分别为 55.9% (N = 175)、24.9% (N = 78) 和 19.2% (N = 60) 的患者。临床T4分期与病理T分期的总体一致率为58.3%，诊断病理T4的临床T4敏感性为41.4%。在 4.6 年的中位随访期内，24.3% 的患者出现疾病复发。大多数复发（超过 80%）发生在 RGC 手术后 2.5 年内，96.1% 发生在 5 年内。腹膜复发在晚期RGC患者中最常见，II期占14.1%，III期占28.3%。多变量回归分析显示，AC 与较长的 RFS 显着相关，风险比为 0.45（95% 置信区间：0.26-0.76）。我们的研究强调了早期检测、准确的术前分期和术后监测在管理晚期疾病中的重要性。研资局案件。尽管存在一些局限性，我们的研究结果表明，AC 可能提供与原发性胃癌相当的生存获益。© 2024。作者获得国际胃癌协会和日本胃癌协会的独家许可。

Clinical findings and postoperative follow-up data on remnant gastric cancer (RGC) are limited due to its rarity. Additionally, the preoperative staging, radical surgery, and managing recurrence in RGC present significant clinical challenges.We analyzed the clinicopathological findings, adjuvant chemotherapy, and patterns of postoperative recurrence of 313 consecutive patients who underwent curative surgery for RGC at 17 Japanese institutions. This study investigated the optimal management of RGC and the impact of adjuvant chemotherapy (AC) on recurrence-free survival (RFS).Pathological stages I, II, and III were observed in 55.9% (N = 175), 24.9% (N = 78), and 19.2% (N = 60) of the patients, respectively. The overall concordance rate between clinical and pathological T staging was 58.3%, with a clinical T4 sensitivity of 41.4% for diagnosing pathological T4. During the median follow-up period of 4.6 years, disease recurrence occurred in 24.3% of patients. Most recurrences (over 80%) occurred within 2.5 years, and 96.1% within 5 years after RGC surgery. Peritoneal recurrence was the most common in patients with advanced RGC, accounting for 14.1% in stage II and 28.3% in stage III. Multivariable regression analysis showed that AC was significantly associated with a longer RFS, with a hazard ratio of 0.45 (95% confidence interval: 0.26-0.76).Our study underscores the importance of early detection, accurate preoperative staging, and postoperative surveillance in managing advanced RGC cases. Despite some limitations, our findings indicate that AC may provide survival benefits comparable to those seen in primary gastric cancer.© 2024. The Author(s) under exclusive licence to The International Gastric Cancer Association and The Japanese Gastric Cancer Association.